In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter.

No abstract is available for this paper.

• Publication year

  2001

• Venue

  Clinical Cancer Research

• Publication date

  2001-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  PMID 11751529
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Robust prostate-specific expression for the targeted gene therapy based on the human kallikrein 2 promoter.

  2002cited by this paper
• Cancer Statistics, 2001

  2001cited by this paper
• In situ gene therapy for prostate cancer: immunomodulatory approaches

  2001cited by this paper
• Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer

  2001cited by this paper
• Robust Prostate-Specific Expression for Targeted Gene Therapy Based on the Human Kallikrein 2 Promoter

  2001cited by this paper
• Secreted caveolin-1 stimulates cell survival/clonal growth and contributes to metastasis in androgen-insensitive prostate cancer.

  2001cited by this paper
• Caveolin-1 mediates testosterone-stimulated survival/clonal growth and promotes metastatic activities in prostate cancer cells.

  2001cited by this paper
• The dual impact of coxsackie and adenovirus receptor expression on human prostate cancer gene therapy.

  2000cited by this paper
• Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer.

  2000cited by this paper
• Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis

  2000cited by this paper
• Elevated caveolin-1 levels in African-American versus white-American prostate cancer.

  2000cited by this paper
• Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines.

  2000cited by this paper
• Prostate‐specific suicide gene therapy using the prostate‐specific membrane antigen promoter and enhancer

  2000cited by this paper
• In Situ Gene Therapy for Adenocarcinoma of the Prostate: A Phase I Clinical Trial

  1999cited by this paper
• Caveolin-1 expression in clinically confined human prostate cancer: a novel prognostic marker.

  1999cited by this paper
• Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastases in an orthotopic model

  1999cited by this paper
• Cooperative therapeutic effects of androgen ablation and adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer

  1999influential reference
• Up-regulation of Caveolae and Caveolar Constituents in Multidrug-resistant Cancer Cells*

  1998cited by this paper
• Metastasis-related Genes in Prostate Cancer: The Role of Caveolin-1

  1998cited by this paper
• Upregulation of caveolin‐1 and caveolae organelles in Taxol‐resistant A549 cells

  1998cited by this paper
• Local inflammatory response and vector spread after direct intraprostatic injection of a recombinant adenovirus containing the herpes simplex virus thymidine kinase gene and ganciclovir therapy in mice.

  1998cited by this paper
• Elevated expression of caveolin is associated with prostate and breast cancer.

  1998cited by this paper
• Suppression of caveolin expression induces androgen sensitivity in metastatic androgen-insensitive mouse prostate cancer cells

  1998cited by this paper
• Adenovirus‐mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer

  1997influential reference
• Identification of a positive regulatory element responsible for tissue-specific expression of prostate-specific antigen.

  1997cited by this paper
• Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotoxic for prostate-specific antigen-positive prostate cancer cells.

  1997cited by this paper
• Caveolae and caveolins.

  1996cited by this paper
• Prostate Cancer Gene Therapy: Herpes Simplex Virus Thymidine Kinase Gene Transduction Followed by Ganciclovir in Mouse and Human Prostate Cancer Models

  1996cited by this paper
• Apoptosis induced in human osteosarcoma cells is one of the mechanisms for the cytocidal effect of Ad5CMV-p53.

  1995cited by this paper
• Loss of p53 function leads to metastasis in ras+myc-initiated mouse prostate cancer.

  1995cited by this paper
• Progression to androgen insensitivity in a novel in vitro mouse model for prostate cancer.

  1995cited by this paper
• Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component.

  1994cited by this paper
• Neurotensin is an autocrine trophic factor stimulated by androgen withdrawal in human prostate cancer.

  1994cited by this paper
• The effect of thymidine kinase transduction and ganciclovir therapy on tumor vasculature and growth of 9L gliomas in rats.

  1994cited by this paper
• Small high grade adenocarcinoma of the prostate in radical prostatectomy specimens performed for nonpalpable disease: pathogenetic and clinical implications.

  1994cited by this paper
• Development of anti-tumor immunity following thymidine kinase-mediated killing of experimental brain tumors.

  1994cited by this paper
• Regression of established macroscopic liver metastases after in situ transduction of a suicide gene.

  1993cited by this paper
• In Vitro Evidence That Metabolic Cooperation Is Responsible for the Bystander Effect Observed with HSV tk Retroviral Gene Therapy

  1993cited by this paper
• Caveolin, a protein component of caveolae membrane coats.

  1992cited by this paper
• Establishment and characterization of a human primary prostatic adenocarcinoma cell line (ND-1).

  1992influential reference
• Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation

  1992cited by this paper
• Manipulation of adenovirus vectors.

  1991cited by this paper
• A comparison of the morphological features of cancer arising in the transition zone and in the peripheral zone of the prostate.

  1991cited by this paper
• Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ.

  1989cited by this paper

• CAVPENET Peptide Inhibits Prostate Cancer Cells Proliferation and Migration through PP1γ-Dependent Inhibition of AKT Signaling

  2024cites this paper
• Caveolin-1: A promising therapeutic target for diverse diseases.

  2021cites this paper
• Leptin promotes proliferation and inhibits apoptosis of prostate cancer cells by regulating ERK1/2 signaling pathway.

  2020cites this paper
• Gene Therapy in Oncology

  2020cites this paper
• Network-pharmacology-based identification of caveolin-1 as a key target of Oldenlandia diffusa to suppress breast cancer metastasis.

  2019cites this paper
• Review on Gene Therapy of Prostate Cancer

  2018cites this paper
• Caveolin and cavin family members: dual roles in cancer.

  2014cites this paper
• Characterisation of enzyme prodrug gene therapy combinations in coated spheroids and vascular networks in vitro

  2012cites this paper
• Monocarboxylate Transporter 4 and Caveolin-1 Expression in Squamous Cell Carcinoma of the Oral Cavity

  2012cites this paper
• Molecular and traditional chemotherapy: a united front against prostate cancer.

  2010cites this paper
• Comparative Study of Metaplastic Breast Carcinoma and Triple-Negative Breast Carcinoma Using Histologic and Immunohistochemical Analyses

  2010cites this paper
• Transcriptional targeting of tumor endothelial cells for gene therapy.

  2009cites this paper
• Chapter 4 The Biology of Caveolae

  2009cites this paper
• The biology of caveolae: achievements and perspectives.

  2009cites this paper
• Caveolin-1 in tumor progression: the good, the bad and the ugly

  2008cites this paper
• Expression of thymidine kinase mediated by a novel non-viral delivery system under the control of vascular endothelial growth factor receptor 2 promoter selectively kills human umbilical vein endothelial cells.

  2008cites this paper
• Virus combinations and chemotherapy for the treatment of human cancers.

  2008cites this paper
• IMMUNO-GENE THERAPY FOR METASTATIC PROSTATE CANCER

  2008cites this paper
• Optimization of conditionally replicative adenovirus for pancreatic cancer and its evaluation in an orthotopic murine xenograft model.

  2008cites this paper
• Clinical implications of caveolins in malignancy and their potential as therapeutic targets

  2008cites this paper
• Caveolin-1 expression in benign and malignant lesions of the breast

  2007cites this paper
• A small chimeric promoter for high prostate‐specific transgene expression from adenoviral vectors

  2007cites this paper
• Novel gene-directed enzyme prodrug therapies against prostate cancer

  2006cites this paper
• Is caveolin-1 a viable therapeutic target to reduce cancer metastasis?

  2006cites this paper
• Award Number: W81XWH-05-1-0593 TITLE: Prostate Cancer Evaluation: Design, Synthesis, and Evaluation of Novel Enzyme-Activated Proton MRI Contrast Agents

  2006cites this paper
• Caveolin-1 as a potential new therapeutic target in multiple myeloma.

  2006cites this paper
• Vector Targeting in Gene Therapy

  2006cites this paper
• Prostate Cancer Evaluation: Design, Synthesis and Evaluation of Novel Enzyme-Activated Proton MRI Contrast Agents

  2006cites this paper
• Is caveolin-1 a viable therapeutic target to reduce cancer metastasis?

  2006cites this paper
• Cancer Gene Therapy

  2005cites this paper
• Gene therapy strategies in prostate cancer.

  2005cites this paper
• Gene therapy in urology: strategies to translate theory into practice

  2005cites this paper
• Caveolin-1 in oncogenic transformation, cancer, and metastasis.

  2005cites this paper
• Formulated Delivery of Enzyme/Pro-Drug and Cytokine Gene Therapy to Promote Immune Reduction of Treated and Remote Tumors in Mouse Models of Prostate Cancer

  2005cites this paper
• Strategies for Prostate Cancer Gene Therapy

  2004cites this paper
• Preclinical evaluation of a prostate-targeted gene-directed enzyme prodrug therapy delivered by ovine atadenovirus

  2004cites this paper
• Macrophages transduced with an adenoviral vector expressing interleukin 12 suppress tumor growth and metastasis in a preclinical metastatic prostate cancer model.

  2003cites this paper
• Current progress in adenovirus mediated gene therapy for patients with prostate carcinoma

  2003cites this paper
• Expression of thymidine kinase driven by an endothelial-specific promoter inhibits tumor growth of Lewis lung carcinoma cells in transgenic mice

  2003cites this paper
• Therapeutic targets for metastatic prostate cancer.

  2003cites this paper
• Gene therpay for prostate cancer

  2002cites this paper
• Gene therapy for prostate cancer: toxicological profile of four HSV-tk transducing adenoviral vectors regulated by different promoters

  2002cites this paper
• Renal medicine and renal transplantation.

  2000cites this paper